A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-30 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Both Takin' It to the Streets and Livin' on the Fault Line reflected Johnston's diminished role in the group following his illness. Restored to fitness and briefly back in the fold, he contributed one original song to Takin' It to the Streets ("Turn It Loose"), and also sang a verse on Simmons' tune "Wheels of Fortune". He also made live appearances with the band in 1976 (documented in a concert filmed that year at the Winterland in San Francisco, excerpts of which appear occasionally on VH1 Classic) but was sidelined once again that fall due to exhaustion. The Doobie Brothers recorded five new Johnston compositions for Livin' on the Fault Line, but Johnston decided the band's direction had strayed too far from their original sound. He left the band he co-founded, withdrew permission for the Doobie Brothers to use the five songs he contributed to Livin' on the Fault Line, and embarked on a solo career that eventually yielded one modestly successful 1979 Warner Brothers album, Everything You've Heard is True, which featured the single "Savannah Nights", and the less successful album Still Feels Good in 1981. Regardless, he received credit for guitars and vocals on Livin' on the Fault Line and was pictured on the album's inner sleeve band photo. During this period of transition, the band also elevated former roadie Bobby LaKind to onstage backup vocalist and percussionist. In the studio, LaKind first contributed percussion to Takin' It to the Streets but had been a member of the band's lighting crew since 1974.
Sulfur may be found by itself and historically was usually obtained in this form; pyrite has also been a source of sulfur. In volcanic regions in Sicily, in ancient times, it was found on the surface of the Earth, and the "Sicilian process" was used: sulfur deposits were piled and stacked in brick kilns built on sloping hillsides, with airspaces between them. Then, some sulfur was pulverized, spread over the stacked ore and ignited, causing the free sulfur to melt down the hills. Eventually the surface-borne deposits played out, and miners excavated veins that ultimately dotted the Sicilian landscape with labyrinthine mines. Mining was unmechanized and labor-intensive, with pickmen freeing the ore from the rock, and mine-boys or carusi carrying baskets of ore to the surface, often through a mile or more of tunnels. Once the ore was at the surface, it was reduced and extracted in smelting ovens. The conditions in Sicilian sulfur mines were horrific, prompting Booker T. Washington to write "I am not prepared just now to say to what extent I believe in a physical hell in the next world, but a sulfur mine in Sicily is about the nearest thing to hell that I expect to see in this life." Sulfur is still mined from surface deposits in poorer nations with volcanoes, such as Indonesia, and problems with working conditions still exist. Elemental sulfur was extracted from salt domes (where it sometimes occurs in nearly pure form) until the late 20th century, when it became a side product of other industrial processes such as in oil refining, in which sulfur is undesirable.
A ribosome () is a ribonucleoprotein particle found in all cells that synthesizes proteins by translating genetic information encoded in messenger RNA (mRNA). During translation, the ribosome decodes successive codons in an mRNA molecule and, with the aid of transfer RNA (tRNA), links amino acids into a polypeptide chain. Each ribosome comprises a small and a large subunit, each composed of one or more ribosomal RNA (rRNA) molecules and many ribosomal proteins. Ribosomes differ in size, composition and organization among bacteria, archaea and eukaryotes, but they share a core structure that reflects a common evolutionary origin. Distinct ribosomes are also found in eukaryotic mitochondria and, in plants and algae, chloroplasts. Ribosomes are assembled through ribosome biogenesis, which involves rRNA synthesis and processing together with the assembly of ribosomal proteins into functional subunits. First observed by George Emil Palade in 1955, ribosomes have been the subject of extensive structural and functional research. Their discovery was recognized by the Nobel Prize in Physiology or Medicine in 1974, while determination of their atomic structure and mechanism through X-ray crystallography and cryo-electron microscopy was recognized by the Nobel Prize in Chemistry in 2009.
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most lethal cancers and has a 5-year survival rate of 13%. Pancreatic adenocarcinoma cells resemble pancreatic ductal cells. Both cell groups show tubule formation, cuboidal shape, and ductal markers. Additionally, acinar and endocrine cells have often been found in many of these cancers, demonstrating plasticity and the possibility that the initial target cells are pancreas progenitor cells. Moreover, human tumors usually go with lower-grade lesions that are called pancreatic intraepithelial neoplasias (PanINs) and are in ducts. Because these lesions are in ducts, this means that it is possible that the beginning target cells are ductal cells.
Sources: en.wikipedia.org
=== Ansa-bridging macrolactone === The ansa-bridging macrolactone was constructed following the first Sonogashira coupling, using the Shiina macrolactonization. This protocol was performed on the gram-scale without diminishing its yield employing 2-methyl-6-nitrobenzoic anhydride, 4-dimethylaminopyridine, and triethylamine as a base to promote intramolecular esterification.
K84 produces a bacteriocin (agrocin 84) which is an antibiotic specific against related bacteria, including A. tumefaciens. This method, which was successful at controlling the disease on a commercial scale, had the risk of K84 transferring its resistance gene to the pathogenic Agrobacteria. Thus, in the 1990s, a deletion mutant strain based on K84, known as K1026, was created. This strain is just as successful in controlling crown gall as K84 without the caveat of resistance gene transfer.
=== Commonly-used agents for animals === The quantity of a single anesthetic which is used for balanced techniques has similarity with that which is used for standing sedation. However, compare to the doses used for TIVA (total intravenous anesthesia), which is always lower than using the single anesthetics. The doses of anesthetics required differ, and depend on the required duration of anesthesia, the requirements for anesthesia to volatile, expected pain of injection of anesthesia, the experience the anesthetist using various medicines, and other factors. The pharmacokinetics of the two most common anesthetic agents, xylazine and ketamine, used during the surgical anasthesia are:
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.